Phase I Study of BMS-599626 in Patients With Advanced Solid Malignancies, Including Malignancies That Express HER2.
Phase of Trial: Phase I
Latest Information Update: 03 Oct 2012
At a glance
- Drugs BMS 599626 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- 10 Jun 2017 Biomarkers information updated
- 24 Aug 2005 New trial record.